University Hospital Center Dr Dragiša Mišović

SOCOTEC GROUP WANTS TO ACCELERATE IN MOROCCO AND HAS APPOINTED A NEW GENERAL MANAGER OF SOCOTEC MOROCCO

Retrieved on: 
Monday, November 7, 2022
Muhammad, Growth, Compliance, General manager, ESTP, Congregational mosque, Safety, Real estate, Public sector, Certification, Risk management, Great Mosque of Asilah, Infrastructure, Trusted third party, Bab Oudaya, Engineering, Environment, Building, Construction, Health, University Hospital Center Dr Dragiša Mišović, Retirement, Operational definition, Business engineering, United Kingdom, Deux Rivières (disambiguation)

In good alignment with the dynamism of construction and infrastructure projects in Morocco, as well as renovation projects on existing buildings or equipment, SOCOTEC wants to accelerate in Morocco.

Key Points: 
  • In good alignment with the dynamism of construction and infrastructure projects in Morocco, as well as renovation projects on existing buildings or equipment, SOCOTEC wants to accelerate in Morocco.
  • After the retirement of the previous manager, the SOCOTEC group has just appointed KARIM TOUNOUNTI as General Manager of SOCOTEC MOROCCO and Operational Director of the SOCOTEC Group activities in Morocco from September 2022.
  • He succeeds TAOUFIQ DAOUDI who has established SOCOTEC as a key player in Morocco and undisputed leader in technical control of construction in the country.
  • Karim Tounounti, the new Director of SOCOTEC MOROCCO and SOCO Consult, has an experience of more than 15 years in the Construction industry.

SOCOTEC GROUP WANTS TO ACCELERATE IN MOROCCO AND HAS APPOINTED A NEW GENERAL MANAGER OF SOCOTEC MOROCCO

Retrieved on: 
Monday, November 7, 2022
Muhammad, Growth, Compliance, General manager, ESTP, Congregational mosque, Safety, Real estate, Public sector, Certification, Risk management, Great Mosque of Asilah, Infrastructure, Trusted third party, Bab Oudaya, Engineering, Environment, Building, Construction, Health, University Hospital Center Dr Dragiša Mišović, Retirement, Operational definition, Business engineering, United Kingdom, Deux Rivières (disambiguation)

In good alignment with the dynamism of construction and infrastructure projects in Morocco, as well as renovation projects on existing buildings or equipment, SOCOTEC wants to accelerate in Morocco.

Key Points: 
  • In good alignment with the dynamism of construction and infrastructure projects in Morocco, as well as renovation projects on existing buildings or equipment, SOCOTEC wants to accelerate in Morocco.
  • After the retirement of the previous manager, the SOCOTEC group has just appointed KARIM TOUNOUNTI as General Manager of SOCOTEC MOROCCO and Operational Director of the SOCOTEC Group activities in Morocco from September 2022.
  • He succeeds TAOUFIQ DAOUDI who has established SOCOTEC as a key player in Morocco and undisputed leader in technical control of construction in the country.
  • Karim Tounounti, the new Director of SOCOTEC MOROCCO and SOCO Consult, has an experience of more than 15 years in the Construction industry.

Emercell and Cell-Easy Sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001

Retrieved on: 
Thursday, September 22, 2022
Other Manufacturing, Research, Clinical Trials, Stem Cells, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, Oncology, Institute, Regenerative medicine, Chimeric antigen receptor T cell, Time, Quality control, ATMP, Advanced Therapy Medicinal Product, CGMP, ADI, Stem cell, CAR, Partnership, Immunotherapy, NK, Patient, Ministry of Education (Malaysia), FUI, Technology, SAS, Cell, CDMO, Lymphatic system, Contract, Microsoft, Multimedia, Lymphoma, GMP, Astellas Institute for Regenerative Medicine, University Hospital Center Dr Dragiša Mišović, Vaccine, Fine chemical, Pharmaceutical industry, Exosome

Emercell SAS (Emercell) and Cell-Easy SAS (Cell-Easy) announced today the signing of a strategic agreement for the scale-up and manufacturing of Emercells lead product.

Key Points: 
  • Emercell SAS (Emercell) and Cell-Easy SAS (Cell-Easy) announced today the signing of a strategic agreement for the scale-up and manufacturing of Emercells lead product.
  • Its patented manufacturing process allows a complete industrialization by using the same batch of NK cells for multiple patients.
  • Cell-Easy is an analytics-driven Contract Development and Manufacturing Organization (CDMO) specialized in the production of Gene-modified Cell and Cell Therapy products.
  • Emercell has signed a strategic agreement with Cell-Easy specialized in the development and production of ATMP.

Onward Therapeutics Made a Second Strategic Equity Investment in Emercell for Their NK Cell Technology in Cancer Immunotherapy

Retrieved on: 
Monday, June 20, 2022
ADI, Lymphatic system, NK, FUI, Drug development, Regenerative medicine, Technology, University Hospital Center Dr Dragiša Mišović, CEO, Lymphoma, Institute, ICM, Astellas Institute for Regenerative Medicine, CAR, Company, Cancer, Exercise, Natural killer T cell, Patient, Chimeric antigen receptor T cell, Therapy, Vaccine, Pharmaceutical industry, Épalinges, Biopôle

EPALINGES, Switzerland and MONTPELLIER, France, June 20, 2022 /PRNewswire/ --Onward Therapeutics SA (Onward Therapeutics) and Emercell SAS (Emercell) announced today the recent exercise of Onward Therapeutics' second of three instalments of equity investment in Emercell.

Key Points: 
  • EPALINGES, Switzerland and MONTPELLIER, France, June 20, 2022 /PRNewswire/ --Onward Therapeutics SA (Onward Therapeutics) and Emercell SAS (Emercell) announced today the recent exercise of Onward Therapeutics' second of three instalments of equity investment in Emercell.
  • Emercell has developed a platform technology to produce off-the-shelf natural killer (NK) cells.
  • NK-001 is an optimized cell therapy product consisting of highly activated and alloreactive allogeneic NK cells.
  • Onward Therapeutics is an oncology company focusing on the identification and development of innovative medicines for the treatment of cancer.

The International Myeloma Foundation (IMF) Honors 2022 Research Achievement Awardees, Dr. Hervé Avet-Loiseau and Dr. Bruno Paiva

Retrieved on: 
Wednesday, June 8, 2022
Doctor of Philosophy, R, Multiple myeloma, International Myeloma Foundation, Immunoglobulin M, COVID-19, SNP, Food and Drug Administration, Black swan, European Medicines Agency, MGUS, IMF, In situ hybridization, Fluorescence, Food, Laboratory, Mayo, IFM, MRD, Acute myeloid leukemia, Quality of life, MD, Free University of Brussels (1834–1969), Foundation, Genomics, Biology, EMA, Monoclonality, Doctor of Pharmacy, University, EMMA, Kyle, Patient, India Infoline, Flow cytometry, Teaching hospital, Fish, Risk, Education, WM, MM, AL, NGS, Research, Society, SMM, American Society of Clinical Oncology, Lymphatic system, Disease, ASCO, Chinese, University Hospital Center Dr Dragiša Mišović, BSRI, FDA, Research and development, Gene expression profiling, Board, Pharmaceutical industry, Management, Medicine

The Kyle and Durie Achievement Awards are presented each year to outstanding and deserving individuals who have made significant contributions in the field of myeloma research.

Key Points: 
  • The Kyle and Durie Achievement Awards are presented each year to outstanding and deserving individuals who have made significant contributions in the field of myeloma research.
  • The Robert A. Kyle Lifetime Achievement Award honors individuals whose work have resulted in significant advances in research, treatment, and care of myeloma patients.
  • Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest global foundation focusing specifically on multiple myeloma.
  • In 2012, the IMF launched the Black Swan Research Initiative, a groundbreaking research project aimed at curing myeloma.

BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

Retrieved on: 
Wednesday, May 18, 2022
Cancer, Hapten, Disease, HCL, Ovarian cancer, European Society of Gynaecological Oncology, Center, EMA, Standard of care, Immune system, FRA, OTCQB, University Hospital Center Dr Dragiša Mišović, GMP, Woman, Clinical trial, COVID-19, CSE, III, Hospital, Neoplasm, Company, Survival, Peritoneum, Doctor of Philosophy, Vaccine, Trial of the century, FDA, Obstetrics, Biotechnology, Good, Toxicity, CTA, European Medicines Agency, Heart, Hospices Civils de Lyon, Protein, Severe acute respiratory syndrome coronavirus 2, Cryopreservation, Patient, International Journal of Gynecology & Obstetrics, National Cancer Institute, IND, European Society for Clinical Investigation, Prognosis, Head, ProCare, Usha Menon, Pharmaceutical industry, Medical imaging, Lyon Metropolis, MD, EU, BC

HCL is a public hospital and France's second University Hospital Center, and a premier site for clinical studies in the EU.

Key Points: 
  • HCL is a public hospital and France's second University Hospital Center, and a premier site for clinical studies in the EU.
  • Benot You, MD, PhD, of HCL who are planned Clinical Investigators for the Phase I study of BVX-0918.
  • BioVaxys is preparing to file a Clinical Trial Application ("CTA") with the European Medicines Agency ("EMA") later in 2022.
  • Access to surgically removed ovarian cancer tumor cells is a critical step enabling BioVaxys to validate the manufacturing process for BVX-0918.

BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

Retrieved on: 
Wednesday, May 18, 2022
Cancer, Hapten, Disease, HCL, Ovarian cancer, European Society of Gynaecological Oncology, Center, EMA, Standard of care, Immune system, FRA, OTCQB, University Hospital Center Dr Dragiša Mišović, GMP, Woman, Clinical trial, COVID-19, CSE, III, Hospital, Neoplasm, Company, Survival, Peritoneum, Doctor of Philosophy, Vaccine, Trial of the century, FDA, Obstetrics, Biotechnology, Good, Toxicity, CTA, European Medicines Agency, Heart, Hospices Civils de Lyon, Protein, Severe acute respiratory syndrome coronavirus 2, Cryopreservation, Patient, International Journal of Gynecology & Obstetrics, National Cancer Institute, IND, European Society for Clinical Investigation, Prognosis, Head, ProCare, Usha Menon, Pharmaceutical industry, Medical imaging, Lyon Metropolis, MD, EU, BC

HCL is a public hospital and France's second University Hospital Center, and a premier site for clinical studies in the EU.

Key Points: 
  • HCL is a public hospital and France's second University Hospital Center, and a premier site for clinical studies in the EU.
  • Benot You, MD, PhD, of HCL who are planned Clinical Investigators for the Phase I study of BVX-0918.
  • BioVaxys is preparing to file a Clinical Trial Application ("CTA") with the European Medicines Agency ("EMA") later in 2022.
  • Access to surgically removed ovarian cancer tumor cells is a critical step enabling BioVaxys to validate the manufacturing process for BVX-0918.

Molecular Partners Present Data Demonstrating Successful Inhibition of COVID19 Viral Variants with Ensovibep at the 2021 ISIRV-WHO Conference

Retrieved on: 
Wednesday, October 20, 2021
Spiez Laboratory, Clinical trial, World, DARPin, NASDAQ, Molecular Partners, Death, Risk, WHO, Form, RSV, Twitter, Private Securities Litigation Reform Act, COVID-19, Ophthalmology, Humanitarian use licenses, Part, Incidence, Treatment, Molecule, Security (finance), SPR, University Hospital Center Dr Dragiša Mišović, ACTIV, Surface plasmon resonance, Severe acute respiratory syndrome coronavirus 2, Infection, Complementarity, World Health Organization, International Society, U.S. Securities and Exchange Commission, Investor, NIH, Vaccination, Viral load, Company, GLOBE, Patient, University, RBD, Population, SEC, Novartis, Marketing, Therapy, ACE2, University of Lausanne, Pharmaceutical industry, Vaccine

In addition, the Company will present a Trial in Progress poster on the EMPATHY clinical trial, conducted in collaboration with Novartis.

Key Points: 
  • In addition, the Company will present a Trial in Progress poster on the EMPATHY clinical trial, conducted in collaboration with Novartis.
  • As such, we must continually test ensovibep against new variants to ensure it has the potential to still be relevant for current and future patients.
  • Finally, viral passaging experiments show ensovibep as comparable to monoclonal antibody cocktails with respect to minimizing the development of escape mutants.
  • Molecular Partners and Novartis are collaborating on the development of ensovibep and are evaluating it in global late-stage study.